Sublingual tablet to treat grass pollen allergyJanuary 14, 2019
Stallergenes Greer, a biopharmaceutical company specialising in treatments for respiratory allergies, said it received approval from the USFDA for the extension of the indication for Oralair, a sublingual tablet, to treat patients ages five to nine with grass pollen-induced allergic rhinitis.
Oralair is the only allergy immunotherapy tablet that contains grass pollens from five of the most common grasses (Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass) in the United States. The mixed pollen extract received FDA approval in patients ages ten to 65 in 2014.
Oralair is indicated as immunotherapy for the treatment of grass pollen-induced allergic rhinitis for any of the five grass species contained in the product.
It has been approved based on results from double-blind, placebo-controlled trials in Europe and the United States in over 2,500 adults and children. The results of these trials demonstrated that pre-seasonal and co-seasonal treatment reduces patients’ allergy symptoms and their need for symptom-relieving medication.